Nepal National
NepalNational.com Friday 12th March 2010 Issue 20100312
  • More Breaking Health News

  • Patients suffer as Jammu medical college employees intensify strike
  • Molecule that can switch off cancer discovered
  • Agra villagers suffer from water contamination
  • Have pre-marriage health check: Chinese official
  • Now, sticking plaster that can cure cancer
  • Using home cervical cancer testing kits can increase diagnosis
  • Body's response to taste or smell of meal 'a diabetes risk factor'
  • Flu during pregnancy may raise baby's schizophrenia risk
  • Philippines police raid kidnappers den and released kidnapped Indian man
  • New Chile president takes office as earth continues to shake
  • Gates says Gulf countries are worried about Iran
  • CIA allegedly engaged in LSD experiment in France
    Get Breaking Health News headlines emailed to you daily.

    Popular anti-depressant interferes with breast cancer treatment
    Nepal National
    Tuesday 9th February, 2010  
    (ANI)


    London, Feb 9 : Taking a popular anti-depressant could slash chances of survival for women battling breast cancer, says a new study.

    Seroxat can interfere with a key breast cancer drug, say experts.

    Women taking tamoxifen to fight breast tumours were less likely to survive if they also took the antidepressant, reports The Daily Express.

    The researchers said the results had "major implications for clinical practice" and warned women on Seroxat to see their GP.

    In the British Medical Journal study, researchers from the University of Toronto looked at 2,430 women aged over 66 who were taking tamoxifen and one of five anti-depressants. Those taking Seroxat were more likely to die from breast cancer and were slightly more likely to die from any other cause compared with women not on Seroxat.

    The authors said: "Our findings indicate that the choice of anti
    ­depressant can significantly affect survival in women receiving tamoxifen for breast cancer."

      Email this story to a friend

    Have your say on this story

    Your nickname (optional)
    Message